This week, Dave Kemp takes a closer look at how innovations in genetic screening technology are having a clinical impact to preserve the hearing of at-risk infants. He is joined by Dr. John McDermott, Dr. Nicola Booth and Dr. Gino Miele, to discuss how Genedrive's point-of-care genetic testing device is allowing clinicians to determine whether a child is at increased risk of permanent hearing loss from aminoglycoside use due to a genetic variant.

This type of analysis has traditionally taken days, or even weeks to obtain, can now be done in under an hour on-site. The Genedrive test is rapid, portable, and cost-effective, making it an attractive option for hospitals and clinics. With this technology, doctors can quickly identify at-risk babies and take action to prevent hearing loss.

Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and Twitter: